Treatment Innovations

Revolutionizing Pharmacy Operations: How BD and Wellstar are Deploying AI to Secure the Medication Supply Chain revolutionizing-pharmacy-operations-how-bd-and-wellstar-are-deploying-ai-to-secure-the-medication-supply-chain

Revolutionizing Pharmacy Operations: How BD and Wellstar are Deploying AI to Secure the Medication Supply Chain

Dwi Wanna May 15, 2026

In an era where healthcare systems are grappling with rising labor costs, persistent drug shortages, and the...

Glooko Receives FDA Clearance for EndoTool IV Cloud: A New Era in Hospital Diabetes Management glooko-receives-fda-clearance-for-endotool-iv-cloud-a-new-era-in-hospital-diabetes-management

Glooko Receives FDA Clearance for EndoTool IV Cloud: A New Era in Hospital Diabetes Management

Dwi Wanna May 15, 2026

In a significant advancement for inpatient diabetes care, Glooko has secured US Food and Drug Administration (FDA)...

Aardvark Therapeutics Faces Existential Crossroads Following Clinical Hold on Lead Asset ARD-101 aardvark-therapeutics-faces-existential-crossroads-following-clinical-hold-on-lead-asset-ard-101

Aardvark Therapeutics Faces Existential Crossroads Following Clinical Hold on Lead Asset ARD-101

Ammar Sabilarrohman May 15, 2026

By Jonathan Gardner | BioPharma Dive Published May 15, 2026 In a development that has sent shockwaves...

The GLP-1 Paradox: Pharmaceutical R&D Productivity Rebounds, But at What Cost? the-glp-1-paradox-pharmaceutical-rd-productivity-rebounds-but-at-what-cost-1

The GLP-1 Paradox: Pharmaceutical R&D Productivity Rebounds, But at What Cost?

Laily UPN May 15, 2026

After years of grappling with declining R&D returns and the "post-pandemic hangover," the global biopharmaceutical sector has...

Butterfly Medical Secures $21M Series C Funding as Pivotal BPH Trial Concludes butterfly-medical-secures-21m-series-c-funding-as-pivotal-bph-trial-concludes

Butterfly Medical Secures $21M Series C Funding as Pivotal BPH Trial Concludes

Laily UPN May 15, 2026

In a significant stride for urological healthcare, Butterfly Medical has announced the successful completion of its pivotal...

Rivermark Medical Secures $20 Million Series D to Advance Minimally Invasive BPH Treatment rivermark-medical-secures-20-million-series-d-to-advance-minimally-invasive-bph-treatment

Rivermark Medical Secures $20 Million Series D to Advance Minimally Invasive BPH Treatment

Dwi Wanna May 15, 2026

Wisconsin-based medical technology firm Rivermark Medical has announced the successful closure of a $20 million Series D...

Revvity Bolsters Endocrine Diagnostics: FDA Clears Automated Total Testosterone Assay revvity-bolsters-endocrine-diagnostics-fda-clears-automated-total-testosterone-assay

Revvity Bolsters Endocrine Diagnostics: FDA Clears Automated Total Testosterone Assay

Laily UPN May 15, 2026

In a significant advancement for clinical endocrinology, Revvity has secured US Food and Drug Administration (FDA) clearance...

Navigating the Tightrope: Regenxbio’s Bid for Duchenne Gene Therapy Approval Amid Regulatory Flux navigating-the-tightrope-regenxbios-bid-for-duchenne-gene-therapy-approval-amid-regulatory-flux

Navigating the Tightrope: Regenxbio’s Bid for Duchenne Gene Therapy Approval Amid Regulatory Flux

Suro Senen May 15, 2026

By Ben Fidler | May 14, 2026 The race to redefine treatment for Duchenne muscular dystrophy (DMD)...

The Great Pivot: BioNTech’s Strategic Exit from Infectious Disease and Return to Oncology Roots the-great-pivot-biontechs-strategic-exit-from-infectious-disease-and-return-to-oncology-roots

The Great Pivot: BioNTech’s Strategic Exit from Infectious Disease and Return to Oncology Roots

Laily UPN May 14, 2026

The global biotechnology landscape is witnessing a seismic shift as German mRNA pioneer BioNTech, once the face...

Breakthrough in Urological Oncology: AngioDynamics Reports Positive Two-Year Data for NanoKnife IRE System breakthrough-in-urological-oncology-angiodynamics-reports-positive-two-year-data-for-nanoknife-ire-system

Breakthrough in Urological Oncology: AngioDynamics Reports Positive Two-Year Data for NanoKnife IRE System

Suro Senen May 14, 2026

In a significant development for the field of urological oncology, medical technology firm AngioDynamics has announced promising...

Revolutionizing Pharmacy Operations: How BD and Wellstar are Deploying AI to Secure the Medication Supply Chain

Aardvark Therapeutics Faces Existential Crossroads Following Clinical Hold on Lead Asset ARD-101

The GLP-1 Paradox: Pharmaceutical R&D Productivity Rebounds, But at What Cost?

Butterfly Medical Secures $21M Series C Funding as Pivotal BPH Trial Concludes

Rivermark Medical Secures $20 Million Series D to Advance Minimally Invasive BPH Treatment

Revvity Bolsters Endocrine Diagnostics: FDA Clears Automated Total Testosterone Assay

Navigating the Tightrope: Regenxbio’s Bid for Duchenne Gene Therapy Approval Amid Regulatory Flux

The Great Pivot: BioNTech’s Strategic Exit from Infectious Disease and Return to Oncology Roots

Breakthrough in Urological Oncology: AngioDynamics Reports Positive Two-Year Data for NanoKnife IRE System

You may have missed

A New Battlefront Against Aggressive Breast Cancer: OU Researchers Uncover How Tumors Hijack Immune System to Grow Nerves

Influenza mortality in hospitalised patients affected by vaccination

Navigating the Intersection of GLP-1 Medications and Breast Cancer: An Evolving Landscape

The Dual Reality of October: Advocacy, Research, and the Fight Against Metastatic Breast Cancer